Plain-English translation of NCT05086614 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing thymosin-alpha 1, a medication designed to strengthen your immune system, in people who have had surgery to remove high-risk stage II or stage III colorectal cancer. Half of the participants will receive injections of this medication twice a week for 6 months, while the other half will not receive it. Everyone in the trial will also receive standard chemotherapy or radiation therapy according to current treatment guidelines.
After surgery to remove colorectal cancer, some patients are at higher risk of the cancer returning. Researchers believe that strengthening the immune system with this medication might help prevent recurrence and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either receive injections of the medication twice a week for 6 months or to receive standard care without the medication. You will also receive chemotherapy or radiation therapy as your doctor recommends. Throughout the study, you will have regular visits to monitor your health and check for any side effects. The main goal is to track whether cancer returns within 3 years after your surgery.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China